-
Diabetes Dialogue: Understanding Semaglutide (Ozempic) in CKD and T2D
31 Jan 2025 06:45 GMT
… program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care … Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and … disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and …
-
Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes Therapeutics
24 Jan 2025 00:16 GMT
… director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care … focusing on therapeutic advancements in diabetes management.
Hosts discussed the … disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and …
-
Type-1 Diabetes Treatment Market Climbing to 12.5 Billion USD by 2032 at 4.56% CAGR Growth
21 Jan 2025 14:45 GMT
…
Johnson and Johnson
Dexcom
MannKind
Roche
Medtronic
AstraZeneca, and …
Intravenous
Inhalation
Type 1 Diabetes Treatment Market Distribution Channel …
Adolescents
Adults
Type 1 Diabetes Treatment Market Regional Outlook …
-
Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes Technology
16 Jan 2025 23:00 GMT
… focusing on technology advancements in diabetes management.
The discussion highlighted … advancements and updated recommendations in diabetes care, particularly surrounding continuous … for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and …
-
Diabetes Dialogue: The Evolving Role of Registered Dietitian Nutritionists in Obesity
14 Jan 2025 02:12 GMT
… Perspectives!
In this episode of Diabetes Dialogue: Technology, Therapeutics, and … Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others … disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others …
-
MannKind Expands Executive Leadership Team
06 Jan 2025 21:30 GMT
… help more patients worldwide.” About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses … burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung … release. MANNKIND is a registered trademark of MannKind Corporation.
MannKind Contacts:
…
-
Diabetes Dialogue: Leveraging Smart Algorithms for Insulin Optimization with Eran Atlas
06 Jan 2025 18:59 GMT
… program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care … forward, Atlas described how DreamMed Diabetes is expanding its offerings, … disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others …
-
10 Best Diabetes Stocks To Buy Under $10
06 Jan 2025 12:36 GMT
… : Opportunities and Challenges in Diabetes and Obesity Treatment
The management … $6.89
MannKind Corporation (NASDAQ:MNKD) develops inhaled therapies for diabetes, with … other diabetes products like the V-Go insulin delivery device.
MannKind Corporation …
-
Diabetes Dialogue: Exploring New Horizons in Incretin Therapy for Diabetes and Weight Loss
22 Dec 2024 22:15 GMT
… director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care … highlighting their transformative potential for diabetes management and weight loss.
… disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and …
-
Afrezza inhaled insulin meets primary endpoint in phase 3 pediatric diabetes trial
20 Dec 2024 16:56 GMT
… and type 2 diabetes," said Beck.
References:
1. MannKind Announces Six … -Month Results From Phase 3 INHALE-1 Pediatric Diabetes … Trial Utilizing Inhaled Insulin (Afrezza). MannKind Corporation. Press …
About
© 1995-2025